Want to join the conversation?
$PFE reported that US FDA's Arthritis Advisory Committee has approved biosimilar infliximab across all eligible indications by a vote of 21 to 3. $PFE holds exclusive US commercialization rights for Celltrion's nfliximab. FDA is considering infliximab for all indications, including treatment of rheumatoid arthritis and adult ulcerative colitis.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.